Compare O'will Corp. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROCE of 18.66%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 74.41
3
Poor long term growth as Net Sales has grown by an annual rate of 6.79% over the last 5 years
4
Negative results in Dec 25
5
With ROCE of 17.51%, it has a very attractive valuation with a 1.14 Enterprise value to Capital Employed
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,965 Million (Micro Cap)
7.00
NA
0.00%
0.43
17.70%
1.18
Revenue and Profits:
Net Sales:
10,739 Million
(Quarterly Results - Dec 2025)
Net Profit:
232 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.85%
0%
-5.85%
6 Months
-6.11%
0%
-6.11%
1 Year
-60.21%
0%
-60.21%
2 Years
-53.34%
0%
-53.34%
3 Years
-41.26%
0%
-41.26%
4 Years
-33.46%
0%
-33.46%
5 Years
-32.09%
0%
-32.09%
O'will Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.79%
EBIT Growth (5y)
26.02%
EBIT to Interest (avg)
74.41
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
4.01
Tax Ratio
30.80%
Dividend Payout Ratio
19.62%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.66%
ROE (avg)
15.05%
Valuation key factors
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
1.20
EV to EBIT
6.52
EV to EBITDA
5.90
EV to Capital Employed
1.14
EV to Sales
0.23
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
17.51%
ROE (Latest)
17.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
10,739.20
10,913.00
-1.59%
Operating Profit (PBDIT) excl Other Income
403.90
512.80
-21.24%
Interest
18.90
16.50
14.55%
Exceptional Items
0.00
-27.20
100.00%
Consolidate Net Profit
231.70
246.60
-6.04%
Operating Profit Margin (Excl OI)
35.10%
42.20%
-0.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -1.59% vs 2.05% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -6.04% vs -35.60% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
39,156.00
31,775.20
23.23%
Operating Profit (PBDIT) excl Other Income
1,255.80
1,025.30
22.48%
Interest
44.90
11.80
280.51%
Exceptional Items
0.00
0.00
Consolidate Net Profit
916.40
696.00
31.67%
Operating Profit Margin (Excl OI)
29.70%
30.20%
-0.05%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 23.23% vs 1.66% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 31.67% vs 15.75% in Mar 2024
About O'will Corp. 
O'will Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






